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Plants have played a significant role in the treatment of cancer and infectious diseases for the last four decades. The discovery and
introduction to market of paclitaxel, the vinca alkaloids, etoposide, and many antibacterial drugs support drug discovery programs
based on natural products. Natural products have been rediscovered as important tools for drug development despite advances in
combinatorial chemistry, due to the complex molecular structures able to interact with mammalian cell targets. The Brazilian
flora, the most diverse in the world, has become an interesting spot to prospect for new chemical leads or hits due to its species
diversity and associated chemical richness. Screening programs have been established in Brazil as a strategy to identify potentially
active substances. High throughput screening techniques allow for the analysis of large numbers of extracts in a relatively short
period of time, and can be considered one of the most efficient ways of finding new leads from natural products. An updated
review of the current status of the biological screening program is presented and recent results from new antitumoral and antibacterial
chemical leads are discussed.
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The absolute number of cancer deaths is declining, ac-
cording to epidemiological studies in most developed coun-
tries. Nonetheless, cancer is still considered a major pub-
lic health problem, second only to cardiovascular diseases
in mortality rates.1 Systemic chemotherapy for advanced
and metastatic disease has evolved dramatically with the
introduction of new drugs and regimens, either as isolated
treatment, or in adjuvant settings, associated with surgery
or radiation therapy.2 Several new molecules have been de-
veloped into commercially available drugs that originate
from extracts derived from natural resources, such as
paclitaxel, the vinca alkaloids and etoposide.
Infections are still considered one of the main causes
of human and animal morbidity and consequent mortality.
Controlling resistant bacteria is an increasingly challeng-
ing endeavor and is a major concern for specialists around
the world.3-6 The introduction of new antibiotics therefore
became a matter of public health. Fortunately, research in
this area is widespread, and, as for cancer, natural prod-
ucts can be considered one of the main sources of new
drugs. Data published in 19977 and updated in 20038
showed that over 50% of all new antibiotics approved by
the FDA were extracted from natural sources, derived from
a natural lead, or synthesized (or semi-synthesized) based
on a known natural product.
Natural products still play an important role as a source
of new antitumoral and antibacterial leads, despite recent
progress in combinatorial chemistry. Although more than
100,000 synthetic compounds originate from combinato-
rial chemistry at any given time, a high percentage of these
products still do not have the specific spatial structure re-
quired to interact with mammalian targets.9 The design of
new anticancer drugs has entered a new era: combinato-
rial chemistry is now an important tool for the introduc-
tion of new drugs into the market. However, the chemical
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diversity found in natural products offers new and original
options, adding to the thousands of products obtained from
combinatorial chemistry. Compounds isolated from plants,
especially small molecules, frequently show biological ac-
tivities such as inhibition of macromolecular targets, includ-
ing proteins. On the other hand, even an entire library of
synthetic products may fail to show any significant activ-
ity because most of these products usually consist of big
molecules with no distinctive biological activity.10
The effectiveness of drugs such as paclitaxel, docetaxel,
etoposide and the vinca alkaloids11, together with impor-
tant antibiotics such as vancomycin and penicillin,
reperesent a few examples of the importance of natural
products in drug discovery. Moreover, little is known about
the pharmacology or phytochemistry of plants and animals
representative of the biodiversity found in countries such
as Brazil. The number of superior plants is estimated to
be between 200,000 and 250,000 species12 and only ap-
proximately 20% of the plants have been pharmacologically
evaluated.8 Brazil contains 20% of the world’s
biodiversity,13 and over 17% of the Brazilian biodiversity
can be found in the Amazon Rain Forest.14 The Atlantic
Forest contains approximately 35% of the world’s
Angiospermae, and more than 8% of the Pteridophytae.15
In view of this species richness and considering that these
forests are currently considered as major areas for conser-
vation,16 scientific interest in the potential pharmacologi-
cal resources in the Brazilian forests has been renewed.
Bioprospection of natural resources using screening pro-
cedures is not a new technique; although it has been used
for decades, it was implemented in Brazil only recently.
The US/NIH National Cancer Institute (NCI) has a large
screening program capable of testing 10,000 compounds/
extracts per year. More than 114,000 extracts obtained from
35,000 plant species have already been tested in that pro-
gram, and only 4% have shown significant activity.17 Pres-
ently, the NCI bank of extracts has more than 200,000 ex-
tracts from marine and terrestrial plant and animal extracts
and isolated compounds. It was through this program that
some of the important anticancer drugs were discovered,
such as paclitaxel (from Taxus brevifolia Nutt.),
camptothecin (Camptotheca acuminata Decne) and podo-
phyllotoxin/etoposide (semi-synthetically obtained) (from
Podophyllum peltatum L.),18,19 all of which are currently
being routinely used in cancer therapy.
Our group at the Universidade Paulista-UNIP, in São
Paulo, Brazil, focuses on collecting plants from the Ama-
zon rain forest (Manaus, AM) and from Atlantic Forest
(Iguape, Cananéia e Registro, SP). The university continu-
ously provides local facilities – including laboratories,
boats, and personnel – in both regions, as well as a com-
plete infrastructure capable of testing approximately 500
extracts per year in the main laboratory located in São
Paulo.
The establishment of a bank of extracts has been a pri-
ority since the beginning of the project. Special attention,
investment and technical support have been spent in select-
ing and processing plant material. For that reason, today
the laboratory has developed one of the most standardized
banks of extracts, composed of plants native to the Ama-
zon and Atlantic Forests. Due to the enormous biovidersity
of this region, sample collection strategies had to be rigor-
ously defined in order to create a well-established bank of
extracts. Plant collection can be based on native traditional
knowledge, chemotaxonomic information, or random
prospection, i.e., collection of all possible plant samples
containing flower or fruit. The random approach is easier
in the field, where the plants are collected. Special atten-
tion is given to plants in the reproductive cycle, which al-
low for better taxonomic identification. However, there are
advantages and disadvantages to this approach. The advan-
tage is that collecting a good variety of species certainly
adds value to the bank of extracts. Conceivably, a wide va-
riety of plants may lead to a wide variety of pharmaco-
logical activity and phytochemicals, especially once the
random collection contains both the plants used as medi-
cine by traditional communities and the plants that are not
traditionally used but which may still contain active com-
pounds. The downside is the higher investment needed to
perform random collections, due to the diversity of natu-
ral resources. Effort and significant resources are necessary
to process the plants, and more frequent expeditions are
needed to detect flowering of the plants on a regular ba-
sis. The high number of species to be identified, processed
and tested requires well-established and dedicated techni-
cal and scientific personnel.
An important issue in natural product drug discovery
in Brazil is the regulatory laws that control the access to
biodiversity. Bioprospection in Brazil is regulated by strict
laws based on the Convention of Biodiversity. The law ba-
sically regulates access to the Brazilian genetic patrimony
and allows for its bioprospection. Any Brazilian citizen or
foreigner who desires to bioprospect in Brazil must apply
for one license to access the biodiversity and collect ma-
terial, and another to do the biological research. Foreign-
ers must have a Brazilian collaborator. Local authorities are
trying to establish more effective systems to support the
important research efforts developed by established and
prospective scientific institutions in the country, allowing
more widespread, and at the same time controlled,
bioprospection. Foreign support to develop meaningful
steps for finding new drugs is still a necessity, as the Bra-
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zilian authorities and private industries do not have the tra-
dition of investing in basic research. Meanwhile, tapping
the Brazilian biodiversity is a slow and painstaking
endeavor, and the results are slowly showing their poten-
tial.
The UNIP bank of extracts has approximately 2,000
aqueous and organic extracts obtained from different parts
of plants, or from whole plants, depending on biomass
availability. Most of them were collected in the Amazon
Rain Forest, using a laboratory boat especially equipped
for the present project.
After collection, the initial plant processing, such as
cleaning insects and other species from the material and
separating the organs (leaves, stem, fruits, flowers, wood,
roots, barks, etc.), is usually conducted inside the boat, as
are the initial taxonomic identifications up to the level of
gender, whenever possible.
The crude plant material is brought to São Paulo to be
processed. Plant organs are separated and then completely
dried in an air-circulating stove at 40 ºC. The material is
ground in a hammer-mil. The ground material is placed in
glass percolators and an organic extract is obtained through
initial maceration with equal volumes of dichloromethane
and methanol, followed by maceration with water with the
same plant material previously used, resulting in two ex-
tracts from each plant. Solvents from the organic extract
are evaporated with a rotary evaporator and water from
aqueous extracts is lyophilized. The organic and aqueous
dry extracts are kept in freezers at -20 ºC until use.
Two in vitro biological assays were selected to study
the extracts: 1) a cytotoxic assay based on human cancer-
cell lines, and 2) an antibacterial assay performed on four
resistant bacteria (Staphylococcus aureus, Enterococcus
faecalis, Pseudomonas aeruginosa and Escherichia coli).
As both techniques are conduced in 96-well plates, a large
number of samples can be tested in a short period of time,
and only a small amount of each sample is required. This
allows for collection of small samples from each plant and
for the collection of a wide range of species on each boat
trip into the forests. Recollection from a specific plant is
only required when extracts show activity in the screening
assay, and further identification studies are anticipated.
The antitumoral screening assays performed in the
Laboratório de Extração at UNIP are directed against six
human cancer cell lines provided by the National Cancer
Institute (DTP/NCI/NIH/USA). The cancer cell lines were
chosen according to the most prevalent malignant diseases
occurring in Brazil20.The assay is briefly described as fol-
lows21. Suspensions of breast, prostate, lung, colon, cen-
tral nervous system, and leukemia cell lines are prepared
at concentrations of 10,000, 7,500, 7,500, 15,000, 15,000
and 200,000 cells per well, respectively. After one day in-
cubation, samples of extracts are added at an initial con-
centration of 100 µg/mL. Microplates are incubated for 48
h before being analyzed by the SRB colorimetric method.
Analysis is carried out in a microplate reader at 515 nm.
The percentage of lethality is obtained for each sample, and
the extracts that are able to kill 15% of the cell lines are
chosen for fractionation. The fractions are re-evaluated
against the cancer cell lines so that active ones are identi-
fied and subjected to further fractionation. This procedure
continues until the active substances are isolated. The iso-
lated substances are identified using traditional techniques,
such as UV, NMR, MS and IR spectrometer analysis, on a
collaborative basis. Fractionations are being done now with
some of the active extracts.
The antibacterial assay is performed against the above-
mentioned four strains of bacteria, obtained from the
American Type Culture Collection. Briefly, suspensions
with defined concentrations of bacteria are prepared and
transferred to the microplate wells. The extracts are added
to the corresponding wells at a single concentration of 100
mg/mL.22 After 24-h incubation, the extracts are evaluated
and the active ones, i.e., those able to inhibit bacterial
growth, are subjected to the analysis of minimal inhibitory
concentration (MIC) and minimal bactericidal concentra-
tion (MBC). Extracts showing MIC d•200 mg/mL are se-
lected for further bioguided fractionation.
The Laboratório de Extração has now screened over
1,220 plant extracts against the six human cancer cell lines
and four bacteria, totaling 12,200 tests. From the initial
screening processes, 72 extracts showed significant activ-
ity against at least one of the cancer cell lines and 50 ex-
tracts showed antibacterial activity against one or more bac-
teria used in the assay at the initial concentration of 100
mg/mL. Those active extracts were fractionated using solid
phase extraction syringes and a gradient of solvents com-
prised of dichloromethane, acetonitrile, ethanol, methanol
and water. The fractions were tested in the biological as-
says at a concentration of 100 µg/mL. Results are currently
being analyzed and subjected to phytochemical evaluation
in order to further detect the main classes of compounds
responsible for the observed biological activity. The com-
pounds within each active fraction should be isolated and
identified. Other biological assays should be established in
order to evaluate and determine the mechanisms underly-
ing the antitumor or the antibacterial drug activity.
The optimization of drug discovery using screening
techniques and high throughput analysis, as well as the ad-
vancement of techniques involving spectrometry, led to the
identification of tens of thousands of active marine and ter-
restrial natural products, some of which, including
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topotecan, irinotecan and camptothecin from terrestrial
sources and bryostatin, dolastatin-10 and ecteinascidin 743
from marine sources, are now in clinical trial. Prospecting
the Brazilian rain forests is challenging, but the possibil-
ity of new effective compounds supports current efforts in
the search for new lead products.23-30
The encouraging results obtained from the screening
project represent an important step towards the effective
identification of active drugs against cancer and infectious
diseases. Other assays are currently being evaluated and
established to evaluate the potential activity of the plant
extracts against a wide variety of common diseases. Inten-
sive involvement of national and international researchers
and laboratories in the systematic screening of active prod-
ucts is required, and will certainly lead to further introduc-
tion of more effective drugs to treat cancer and other dis-
eases in the medical armamentarium.
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RESUMO
Younes RN, Varella AD, Suffredini IB. Descoberta de novos
fármacos anti-tumorais e anti-bacterianos de extratos
vegetais brasileiros através de screening em larga escala.
Clinics. 2007;62(6):763-8.
Plantas são uma importante fonte de novos protótipos há
pelo menos quatro décadas. A descoberta e introdução no
mercado de paclitaxel, dos alcalóides da vinca, etoposídeo
e muitos agentes antibacterianos têm servido de apoio ao
desenvolvimento de programas de descobrimento de novos
fármacos baseados em produtos naturais. Produtos naturais
foram recentemente redescobertos como importante
ferramenta na descoberta de novos fármacos devido às
estruturas moleculares complexas capazes de interagir com
alvos em células de mamíferos. A flora brasileira, a mais
rica do mundo, tornou-se um importante sítio para
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